摘要
目的：观察亲溶酶体药物ＩＨＷ２体外净化急性髓细胞白血病骨髓（ＢＭ）进行骨髓移植（ＡＢＭＴ）的临床疗效。方法：用ＩＨＷ２体外净化ＡＢＭＴ患者的ＢＭ，冷冻保存后回输给患者。结果：３例患者输用净化处理的ＢＭ后均成功地恢复造血功能。２例患者移植后至今已分别持续缓解超过３６、３４个月。其中１例患者移植前染色体为４６ＸＹ，ｄｅｌ（１６）（ｑ２２），移植后２个月检测为４６ＸＹ正常染色体核型。１例患者于移植后１９个月复发。结论：初步研究显示亲溶酶体药物ＩＨＷ２，用于临床移植患者是安全可行的。
Objective: To observe the clinical effectiveness of IHW2 purged autologous bone marrow transplantation (ABMT) in the treatment of AML patients. Methods: Large volume of bone marrow was purged in vitro by IHW2 and then reinfused to patients for ABMT. Results: All of the three patients transplanted with IHW2 purged autologous bone marrow successfully reconstituted hemopoiesis. Two patients got continuous complete remission for 36+ and 34+ months, respectively. The karyotype of one of the two patient was 46,XY,del(16)(q22) before ABMT and changed to 46,XY in 2 months after transplantation. The third patient relapsed after ABMT 19 months. Conclusion: The preliminary study suggests that IHW2 may have certain purging effect on leukemic cells and is safe for clinical application.
出处
《中华血液学杂志》
CAS
CSCD
北大核心
1998年第6期312-314,共3页
Chinese Journal of Hematology
基金
卫生部基金
关键词
白血病
IHW2
骨髓净化
骨髓移植
自体骨髓移植
Bone marrow transplantation, autologous Bone marrow purging, IHW2 Leukemia
